Title
Blood Loss After Early TXA in Hip Fractures.
The Effects of the Timing of Tranexamic Acid Administration on Blood Loss in Hip Fractures.
Phase
Early Phase 1Lead Sponsor
Community Memorial Health SystemStudy Type
InterventionalStatus
RecruitingIndication/Condition
Hip FracturesIntervention/Treatment
Tranexamic acid ...Study Participants
120Our present study aims to initiate TXA administration immediately upon diagnosis of hip fracture in the Emergency Department. This will be a single blind randomized controlled trial comparing early administration of TXA in the ED in addition to perioperative dosing versus the standard perioperative administration only. The study population will include patients who have sustained a femoral neck, intertrochanteric, or subtrochanteric femur fracture and are undergoing surgical internal fixation or arthroplasty. We will prospectively compare the need for blood transfusion, total and hidden blood loss, postoperative complications, length of stay and readmission within 30 days.
Consent will be obtained for study enrollment from the patient or legal decision maker. The patient will then be randomized and stratified based on the fracture type, fixation method anticipated, and presence of anticoagulation.
Treatment drug and saline placebo will be blinded from the patient. Treatment arm patients will receive a dose of 10 mg/kg of TXA IV as soon as possible in the ED. They will then receive repeat doses prior to skin incision and again after the end of surgery. Control group will receive a placebo dose of normal saline in the ED and then the standard 10 mg/kg TXA doses prior to surgery and again after the end of surgery. The perioperative doses will not be blinded.
10 mg/kg IV TXA in the ED, repeat doses before skin incision and in PACU
100 mL 0.9% normal saline in the ED, 10 mg/kg IV TXA before skin incision and in PACU
Experimental group will receive 10 mg/kg IV TXA while in the Emergency Department, and repeat preoperative and postoperative doses.
Control group will receive 100 mL 0.9% normal saline in the Emergency Department, and 10 mg/kg IV TXA before skin incision and again in post anesthesia care unit.
Inclusion Criteria: Femoral neck, intertrochanteric, subtrochanteric femur fracture Age >18 Undergoing surgical stabilization or arthroplasty by any method as determined by attending surgeon Exclusion Criteria: Age <18 Concomitant fracture Preoperative anemia needing blood transfusion before surgery Severe comorbidity (active cancer, severe pulmonary disease, ESRD) Allergy for tranexamic acid History of acute thromboembolic event (Deep Vein Thrombosis, Pulmonary Embolism, Stroke, TIA) in the previous 12 months Myocardial infarction in the previous 12 months Renal function impairment (creatinine clearance <30 mL/min), or kidney transplant History of hypercoagulability (Factor V Leiden, Protein C/S deficiency)
